Comparison of effects of hormone replacement therapy on serum lipid profile & lipoprotein(a) in post menopausal women in a Tertiary Care Hospital
Keywords:
Lipid profile, Lipoprotein(a), HRT, MenopauseAbstract
Background & Introduction:
Menopause results in a number of problems in women such as sexual dysfunction, atrophic changes, osteoporosis and coronary artery disease. Hormone replacement therapy (HRT) is currently prescribed for the relief of menopausal symptoms and prevention of both post menopausal osteoporosis and coronary heart disease arising from dyslipidemia & atherogenesis.The study was used to compare the effects of combined estrogen progestogen therapy and estrogen alone on serum lipid profile and lipoprotein (a).
Material & Methods:
A prospective longitudinal study was conducted on the patients attending the Gynecology OPD at the All India Institute of Medical Sciences, New Delhi. Thirty women, who have attained spontaneous or surgical menopause, were selected as cases. All the women with natural menopause received combined estrogen-progestogen therapy (CEE, 0.625 mg and medroxyprogesterone acetate 2.5mg daily) for six months. On the other hand the women who underwent surgical menopause received only estrogen (CEE 0.625 mg) daily for six months Lipid Profile parameters & lipoprotein(a) were measured using commercially available kits before commencement of treatment & on follow-up(at 3 & 6 months).
Results:
There was a 30% decrease in serum lipoprotein (a) level following six months of HRT. This finding confirms with the positive cardioprotective effective of estrogen.
Conclusion:
The beneficial effects of estrogen on lipids and lip (a) got partially attenuated when progesterone was added to estrogen.
Downloads
References
References:
McNeil MA, Merriam SB. Menopause. Ann Intern Med. 2021 Jul;174(7):ITC97-ITC112.
US Preventive Services Task Force. Mangione CM, Barry MJ, Nicholson WK, Cabana M, Caughey AB, Chelmow D, Coker TR, Davis EM, Donahue KE, Jaén CR, Kubik M, Li L, Ogedegbe G, Pbert L, Ruiz JM, Stevermer J, Wong JB. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement. JAMA. 2022 Nov 01;328(17):1740-1746.
Hall JE. Endocrinology of the Menopause. Endocrinol Metab Clin North Am. 2015 Sep;44(3):485-96.
Burkard T, Moser M, Rauch M, Jick SS, Meier CR. Utilization pattern of hormone therapy in UK general practice between 1996 and 2015: a descriptive study. Menopause. 2019 Jul;26(7):741-749.
Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023 Feb 07;329(5):405-420.
Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. El Khoudary SR, Aggarwal B, Beckie TM, et al. Circulation. 2020;142:0–32.
Ettinger B Friedman, Bush T : Reduced mortality associated with long-term postmenopausal estrogen therapy. ObstetGynecol 1996; 87 : 5.
Ambikairajah A., Walsh E., Cherbuin N. (2019). Lipid Profile Differences during Menopause: a Review with Meta-Analysis. Menopause 26 (11), 1327–1333.
Baber R. J., Panay N., Fenton A. (2016). 2016 IMS Recommendations on Women's Midlife Health and Menopause Hormone Therapy. Climacteric 19 (2), 109–150. 10.3109/13697137.2015.1129166
Published
How to Cite
Issue
Section
Copyright (c) 2024 Sachi Prasad Basu, Koustuv Chowdhury, Arindam Sur
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.